USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), to develop agonists using its OX40 platform.
MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer. Financial terms of the collaboration have not been disclosed.
"We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx chief executive Llew Keltner, noting that "MedImmune has impressive capabilities in immuno-oncology, and we believe offers great potential for eventually bringing therapies utilizing the OX40 mechanism to trigger tumor-specific immune responses to patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze